|
|
 Previous Article | Table of Contents | Next Article 
Immunotherapy of Multiple Myeloma With a Monoclonal Antibody Directed Against a Plasma Cell-Specific Antigen, HM1.24
Shuji Ozaki,
Masaaki Kosaka,
Shingo Wakatsuki,
Masahiro Abe,
Yasuo Koishihara, and
Toshio Matsumoto
From the First Department of Internal Medicine, School of Medicine, University of Tokushima, Tokushima; and Fuji-Gotemba Research Laboratory, Chugai Pharmaceutical Co, Ltd, Shizuoka, Japan.
Multiple myeloma remains an incurable malignancy because of marked resistance of tumor cells to conventional chemotherapeutic agents. Alternative strategies are needed to solve these problems. To develop a new strategy, we have generated a monoclonal antibody (MoAb), which detects a human plasma cell-specific antigen, HM1.24. In this report, we evaluated the in vivo antitumor effect of unconjugated anti-HM1.24 MoAb on human myeloma xenografts implanted into severe combined immunodeficiency (SCID) mice. Two models of disseminated or localized tumors were established in SCID mice by either intravenous or subcutaneous injection of human myeloma cell lines, ARH-77 and RPMI 8226. When mice were treated with a single intraperitoneal injection of anti-HM1.24 MoAb 1 day after tumor inoculation, the development of disseminated myeloma was completely inhibited. In mice bearing advanced tumors, multiple injections of anti-HM1.24 MoAb reduced the tumor size and significantly prolonged survival, including tumor cure, in a dose-dependent manner. The proliferation of cultured human myeloma cells was inhibited in vitro by anti-HM1.24 IgG-mediated complement-dependent cytotoxicity, but not by the antibody alone. Moreover, spleen cells from SCID mice mediated antibody-dependent cell cytotoxicity against RPMI 8226 cells. These results indicate that anti-HM1.24 MoAb can be used for immunotherapy of multiple myeloma and related plasma cell dyscrasias.
Blood, Vol. 90 No. 8 (July 15), 1997:
pp. 3179-3186
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Sekimoto, S. Ozaki, T. Ohshima, H. Shibata, T. Hashimoto, M. Abe, N. Kimura, K. Hattori, S. Kawai, Y. Kinoshita, et al.
A Single-Chain Fv Diabody against Human Leukocyte Antigen-A Molecules Specifically Induces Myeloma Cell Death in the Bone Marrow Environment
Cancer Res.,
February 1, 2007;
67(3):
1184 - 1192.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Jalili, S. Ozaki, T. Hara, H. Shibata, T. Hashimoto, M. Abe, Y. Nishioka, and T. Matsumoto
Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma
Blood,
November 15, 2005;
106(10):
3538 - 3545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B. Rew, K. Peggs, I. Sanjuan, A. R. Pizzey, Y. Koishihara, S. Kawai, M. Kosaka, S. Ozaki, B. Chain, and K. L. Yong
Generation of Potent Antitumor CTL from Patients with Multiple Myeloma Directed against HM1.24
Clin. Cancer Res.,
May 1, 2005;
11(9):
3377 - 3384.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Walter-Yohrling, X. Cao, M. Callahan, W. Weber, S. Morgenbesser, S. L. Madden, C. Wang, and B. A. Teicher
Identification of Genes Expressed in Malignant Cells That Promote Invasion
Cancer Res.,
December 15, 2003;
63(24):
8939 - 8947.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Abe, K. Hiura, J. Wilde, K. Moriyama, T. Hashimoto, S. Ozaki, S. Wakatsuki, M. Kosaka, S. Kido, D. Inoue, et al.
Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma
Blood,
August 28, 2002;
100(6):
2195 - 2202.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M.-Y. Sze, G. Giesajtis, R. D. Brown, M. Raitakari, J. Gibson, J. Ho, A. G. Baxter, B. Fazekas de St Groth, A. Basten, and D. E. Joshua
Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+CD57+CD28- compartment
Blood,
November 1, 2001;
98(9):
2817 - 2827.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ozaki, M. Kosaka, Y. Wakahara, Y. Ozaki, M. Tsuchiya, Y. Koishihara, T. Goto, and T. Matsumoto
Humanized Anti-HM1.24 Antibody Mediates Myeloma Cell Cytotoxicity That Is Enhanced by Cytokine Stimulation of Effector Cells
Blood,
June 1, 1999;
93(11):
3922 - 3930.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Treon, J. A. Mollick, M. Urashima, G. Teoh, D. Chauhan, A. Ogata, N. Raje, J. H.M. Hilgers, L. Nadler, A. R. Belch, et al.
Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induced by Dexamethasone
Blood,
February 15, 1999;
93(4):
1287 - 1298.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
